French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US-based biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) on Wednesday announced positive results from a phase 3 study of Dupixent (dupilumab) for patients with uncontrolled chronic spontaneous urticaria (CSU).
The study, LIBERTY-CUPID Study C, found that Dupixent significantly reduced itch and urticaria activity compared to placebo.
These results build on the findings of an earlier phase 3 study, CUPID-A, and support regulatory resubmission in the United States by the end of the year. If approved, Dupixent would be the first targeted therapy for CSU in a decade.
CSU is a chronic skin condition characterised by sudden, debilitating hives and persistent itch. It can significantly impact quality of life for affected patients.
The study enrolled 151 patients who were randomised to receive Dupixent or placebo in addition to standard-of-care antihistamines.
At 24 weeks, Dupixent-treated patients experienced a greater reduction in itch severity and urticaria activity compared to those receiving placebo. Additionally, a higher percentage of Dupixent-treated patients reported complete remission of their urticaria.
The safety profile of Dupixent in this study was generally consistent with its known safety profile in other approved indications.
Sanofi plans to submit detailed results from the study to the US Food and Drug Administration (FDA) in support of its supplemental biologics application for Dupixent in CSU.
NCI reports IND submission for pilot study of Senhwa Biosciences Inc's developed Pidnarulex
Epitomee Medical's Capsule cleared by FDA for weight management
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Neuspera Medical names new chief operating officer
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024